Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Revvity Q3 2026 Results: Net Income $62.3M, Up 33.5% YoY

Revvity, Inc. reported total revenue of $728.9 million for the third quarter of 2026, a 4% increase compared to the same period in 2025. Net income for the quarter rose to $62.3 million, up from $46.7 million year-over-year, while the company continued to execute its share repurchase program, reducing outstanding common stock to approximately 111.6 million shares.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue728.9698.9
Profit before tax77.755.7
Net income62.346.7
EPS (diluted, $ a share)$0.56$0.40

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+33.5%
Revenue, year on year+4.3%
Operating margin13.1%
Source

10-Q filed with the SEC, NYSE: RVTY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Revvity, Inc.: key numbers

Share price
$148.85Close, Nov 16
Market cap
$16.6B
Shares outstanding
111.64MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Revvity, Inc.

All →
8:11 AM ET 8-K
Investor Presentation

Revvity Investor Presentation

Revvity is hosting its 2026 Investor Day to showcase its 'Powering Scientific Intelligence' strategy, focusing on AI-enabled discovery workflows and its Life Sciences and Diagnostics portfolio. Management will outline strategic priorities, operational initiatives, and the company's long-range financial outlook to investors.

8:17 AM ET 8-K
Financial Results

Revvity Financial Results

Revvity reported third quarter 2026 financial results with revenue of $729 million and adjusted EPS of $1.38, exceeding expectations. The company raised its full-year guidance and provided pro forma financials reflecting the pending $200 million divestiture of its China Immunodiagnostics business. Management noted improving end-market conditions and strong execution across its Life Sciences and Diagnostics segments.

“Our exceptional third quarter performance demonstrates the momentum building across Revvity, as broad-based growth and strong execution drove results meaningfully ahead of our expectations. With end market conditions continuing to improve, a strong pipeline of innovation, and the benefits of our transformation increasingly evident in our results, Revvity is extremely well positioned to capitalize on the opportunities ahead.”

Prahlad Singh, president and chief executive officer of Revvity
4:05 PM ET Form 4
Insider Selling

Revvity VP and CAO Anita Gonzales Sells $13.1K of Stock

Anita Gonzales, VP and CAO, sold 84 shares of Revvity, Inc. at $155.48 a share, worth $13.1K in total on Oct 1, 2026. Shares held after the trade: 7,117 (-1.2%).

Value
$13.1K
Shares
84
Price
$155.48
Role
VP and CAO
Holding change
-1.2%
Trade date
Oct 1, 2026
4:05 PM ET Form 4
Insider Selling

Revvity Please See Remarks Tajinder S. Vohra Sells $1.03M of Stock

Tajinder S. Vohra, Please See Remarks, sold 7,330 shares of Revvity, Inc. at $140.88 a share, worth $1.03M in total on Sep 16, 2026. Shares held after the trade: 6,635 (-52.5%).

Value
$1.03M
Shares
7,330
Price
$140.88
Role
Please See Remarks
Holding change
-52.5%
Trade date
Sep 16, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.